Edelris and Bridge Biotherapeutics Extend Their Collaboration To Discover Novel Covalent Probes

Edelris, an innovative French research and services company focused on Hit generation and Hit-to-Lead optimization, and Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for inflammation, fibrosis and oncology, today announced the extension of their successful chemical discovery collaboration.

Based on its track record of expertise in complex chemical biology and medicinal chemistry, Edelris will strengthen its team dedicated to the Bridge Biotherapeutics discovery program. The goal of the collaboration is to find novel reactive groups that target non-cysteine residues, with the objective of uncovering new druggable sites in oncology and immunology targets that are of high therapeutic value. The collaboration between Bridge Biotherapeutics and Edelris began in 2021.

B. Christopher Kim, Ph.D., Executive Vice President of Bridge Biotherapeutics, said, “We have been very pleased to work with Edelris for our drug discovery activities focused on novel and reactive chemistries targeting oncogenic mutations of therapeutic targets. We are working to develop a novel and tunable scientific platform to develop highly selective compounds to address unmet needs in numerous disease states.”
“Edelris is proud to actively contribute to the discovery efforts of innovative biotech company like Bridge Biotherapeutics and help them reach their goal of addressing unmet therapeutic needs. Their bold strategic and scientific vision fits perfectly with our in-depth expertise in challenging drug discovery projects” said Dr. Jean-Yves Ortholand, CEO of Edelris. “We are eager to support additional breakthroughs as the program moves forward.”

About Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotech company based in the Republic of Korea, with offices in the U.S. and China. Founded in 2015, Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics for disease indications with high unmet medical need, including cancer, ulcerative colitis, and fibrotic diseases. The company’s pipeline includes BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. For more information, visit https://www.bridgebiorx.com/en/.